|
May 13
|
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
|
May 9
|
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
|
|
May 8
|
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call Transcript
|
|
May 8
|
XFOR: Data from Phase 2 CN Trial Expected in June 2024…
|
|
May 8
|
X4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
|
|
May 7
|
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
|
|
Apr 30
|
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
|
|
Apr 30
|
XFOR: XOLREMDI™ Approved by FDA…
|
|
Apr 29
|
UPDATE 1-US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease
|
|
Apr 29
|
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
|
|
Apr 11
|
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns
|
|
Apr 2
|
XFOR: PDUFA Date of April 30, 2024 for Mavorixafor for WHIM Syndrome…
|
|
Apr 1
|
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
|
|
Mar 22
|
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript
|
|
Mar 22
|
Q4 2023 X4 Pharmaceuticals Inc Earnings Call
|
|
Mar 21
|
X4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 Financial Results
|
|
Mar 21
|
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
|
|
Mar 12
|
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
|
|
Dec 9
|
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
|
|
Dec 4
|
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|